DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

Center for Biologics Evaluation and Research

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.

Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.

Office of Biotechnology Products

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

1 Overview: Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies Raj K. Puri, M.D., Ph.D. Director, DCGT Office of Cellular,

The Life Cycle of an NIH Grant Application Alicia Dombroski, Ph.D. Deputy Director Division of Extramural Activities NIDCR.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

ACPS October Nanotechnology: Issues and Future Directions Nakissa Sadrieh Ph.D. OPS/CDER/FDA.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

The evaluation of research units at HCERES

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

1 Update on Nanotechnology Activities in CDER and FDA Keith O. Webber, Ph.D. Deputy Director OPS/CDER/FDA ACPS Meeting Tuesday, July 22, 2008.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Raj K. Puri, M.D., Ph.D. Director, DCGT

ACPS Meeting, October 19-20, 2004 BioINequivalence: Concept and Definition Lawrence X. Yu, Ph. D. Director for Science Office of Generic Drugs, OPS, CDER,

Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

Dietary Supplement Research Centers: Botanicals RFA OD Applicant Information Meeting February 6, 2004 Bethesda MD Christine A. Swanson, Ph.D. Office.

Office of Science U.S. Department of Energy Marvin Frazier Director, Life Sciences Division Office of Biological and Environmental Research April 30, 2004.

Center for Biologics Evaluation and Research, FDA Kathryn M. Carbone, M.D. Associate Director for Research.

Promotions on the Clinician Educator Track Larry L. Swift, Ph.D. Vice Chair for Faculty Affairs Department of Pathology, Microbiology & Immunology.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

NOAA Cooperative Institutes John Cortinas, Ph.D. OAR Cooperative Institute Program, Program Manager NOAA Cooperative Institute Committee, Chairperson.

HANC and Community Partners Overview November 20, 2007 Michael Petillo, Project Coordinator.

The Tenure Process: Internal Establish an independent program with a clear focus that is innovative and takes advantage of our resources here at NCI and.

UPDATE: Nonclinical Reproductive Toxicity Information in Assessing Human Risk Joseph J. DeGeorge Ph.D. Associate Director for Pharmacology and Toxicology.

Rapid Response Team Nakissa Sadrieh, Ph.D. Associate Director for Research Policy and Implementation, OPS.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.

Office of Vaccines Research and Review

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Promotions on the Physician Scientist/Basic Science Investigator Track Larry L. Swift, Ph.D. Vice Chair for Faculty Affairs Department of Pathology, Microbiology.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

RDRC Membership: SNM Suggestions Mathew L. Thakur, Ph.D. President Society of Nuclear Medicine.

CBER Research: OBRR Office Site Visit Kathryn M. Carbone, MD Associate Director of Research CBER/FDA.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Report of the Committee of Visitors of the Division of Materials Science and Engineering (DMSE) to the Basic Energy Sciences Advisory Committee Review.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Peer Review of OBP Research Division of Monoclonal Antibodies

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

CBER Research: OCTGT Office Site Visit Carolyn A. Wilson, Ph.D. Associate Director of Research (Acting) CBER/FDA.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

The Lead Agency Council Sports Trust (Sport Otago) Cluster of clubs Interested parties / other.

Nonclinical Studies Subcommittee John Doull, M.D., Ph.D., Chair Advisory Committee for Pharmaceutical Science November 15, 2000.

1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.

STRENGTHENING FORENSIC SCIENCE IN THE UNITED STATES: A PATH FORWARD The Future of Forensic Science John Marshall Law Center, Cleveland, OH 19 March 2009.

Georgetown UNIVERSITY Overview of Gene Transfer as an Evolving Neurotherapeutic Modality Howard J Federoff, MD, PhD Georgetown University Medical Center.

Being an effective consumer of preclinical research

From Bench to Clinical Applications: Money Talks

Nanotechnology: Issues and Future Directions

Presentation transcript:

DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA

OUTLINE THE NEED THE LABS THE PLAN THE FUTURE

WHY IS AN INDEPENDENT EVALUATION NEEDED? OBJECTIVE ASSESSEMENT OF: SCIENTIFIC RIGOR & THOROUGHNESS SCIENTIFIC PRODUCTIVITY MISSION RELEVANCE OBJECTIVE RECOMMENDATIONS FOR: FUTURE DIRECTIONS RESOURCE ALLOCATIONS PROMOTIONS & CONVERSIONS

RESEARCH OFFICES OFFICE OF PHARMACEUTICAL SCIENCE OFFICE OF TESTING AND RESEARCH DIVISION OF APPLIED PHARACOLOGY RESEARCH DIVISION OF PHARMACEUTICAL ANALYSIS DIVISION OF PRODUCT QUALITY RESEARCH LABORATORY OF CLINICAL PHARMACOLOGY OFFICE OF BIOTECHNOLOGY PRODUCTS DIVISION OF MONOCLONAL ANTIBODIES DIVISION OF THERAPEUTIC PROTEINS

OPS LABORATORIES OTR - Division of Pharmaceutical Analysis St. Louis, MO OTR - Lab of Clinical Pharmacology - Division of Applied Pharmacology Research - Division of Product Quality Research White Oak, MD OBP - Div. Of Monoclonal Antibodies - Div. of Therapeutic Proteins Bethesda, MD

OFFICE OF TESTING AND RESEARCH RESEARCH PROGRAM EXAMPLES: ANALYTICAL METHOD DEVELOPMENT AND CHARACTERIZATION PAT TOOLS –NIR, RAMAN, TERAHERTZ SPECTROSCOPY –CHEMICAL IMAGING TECHNOLOGIES PRODUCT TESTING –SUPPORT BIOEQUIVALENCE CHALLENGES –STABILITY OF REPACKAGED DRUGS –TRANSDERMAL DELIVERY SYSTEMS DEVELOPMENT OF BIOMARKERS OF TOXICITIES DEVELOPMENT AND STANDARDIZATION OF GENOMICS METHODOLOGIES NANOTECHNOLOGY EVALUATION OF ANALYTICAL METHODS IN NDAs

OFFICE OF BIOTECHNOLOGY PRODUCTS RESEARCH PROGRAM EXAMPLES: MECHANISMS OF HUMORAL AND CELL-MEDIATED IMMUNE RESPONSES AND TOLERANCE INTERACTIONS BETWEEN HIV, CYTOKINES, AND CELLS OF THE IMMUNE SYSTEM MECHANISMS OF ANTHRAX LETHAL TOXIN MECHANISMS OF ONCOGENESIS AND TUMOR CELL DESTRUCTION MODERNIZATION OF VIRAL SAFETY APPROACHES AND TECHNOLOGY MECHANISMS OF SIGNAL TRANSDUCTION NOVEL METHODS FOR SYNTHESIS OF OLIGONUCLEOTIDES

SCIENCE REVIEW: DONE INTERNALLY (OPS) PROMOTIONS (GS-13  GS-14): LABORATORY SCIENTIST PEER REVIEW COMMITTEE MEETS ON AN AD HOC BASIS TO EVALUATE SCIENTIFIC QUALIFICATIONS AND CONTRIBUTIONS OF: –RESEARCH SCIENTISTS PROPOSED FOR PROMOTION –ALL RESEARCH SCIENTISTS AT GS-14 AND ABOVE TO BE REVIEWED EVERY 3 YEARS OFFICE OF TESTING AND RESEARCH

MIXED INTERNAL & EXTERNAL MEMBERSHIP 3 MEMBERS FROM CDER –DIVISION DIRECTORS OR SENIOR SCIENTIST LEVEL 3 MEMBERS FROM OUTSIDE –SCIENTISTS FROM NIH OR OTHER FDA CENTERS REP FROM HUMAN RESOURCES MANAGEMENT EXEC SEC FROM OTR OFFICE OF TESTING AND RESEARCH LABORATORY SCIENTIST PEER REVIEW COMMITTEE

OFFICE OF BIOTECHNOLOGY PRODUCTS EXTERNAL SITE-VISIT COMMITTEE MEMBERSHIP –CHAIR FROM ADVISORY COMMITTEE –1 OR 2 SELECTED SCIENTISTS PER PRINCIPAL INVESTIGATOR –EXECUTIVE SECRETARY FROM AD-COM

OFFICE OF BIOTECHNOLOGY PRODUCTS PROMOTION, CONVERSION, EVALUATION COMMITTEE PEER-REVIEW PURPOSE –CONVERSION OF STAFF FELLOWS TO CIVIL SERVICE POSITIONS –PROMOTION OF CIVIL SERVICE RESEARCHERS

OFFICE OF BIOTECHNOLOGY PRODUCTS PROMOTION, CONVERSION, EVALUATION COMMITTEE MEMBERSHIP –2 TENURED PRINCIPAL INVESTIGATORS FROM EACH PRODUCT OFFICE IN CBER, PLUS OBP (TOTAL = 10) –2 FULL-TIME REVIEWERS –1 HUMAN RESOURCE MANAGEMENT REP. –1 REP FROM CBER CENTER-DIRECTOR’S OFFICE

CURRENT OTR SYSTEM GS-13 SCIENTIST PEER REVIEW GS-14 SCIENTIST EVERY 3 YEARS

CURRENT OBP SYSTEM SENIOR STAFF FELLOW OR GS PRINCIPAL INVESTIGATOR SITE VISIT RECOMMEND- ATION PROMOTION, CONVERSION, EVALUATION COMMITTEE PROMOTION OR CONVERSION OF STAFF MEMBER EVERY 4 YEARS

WORKING GROUP FOR DESIGNING REVIEW PROGRAM OFFICE OF TESTING AND RESEARCH: JOHN STRONG, PH.D. MANSOOR KHAN, PH.D. LUCINDA BUHSE, PH.D. NAKISSA SADRIEH, PH.D. OFFICE OF BIOTECHNOLOGY PRODUCTS: KATHLEEN CLOUSE-STREBEL, PH.D. ELIZABETH (WENDY) SHORES, PH.D. ED MAX, M.D., PH.D. EMILY SHACTER, PH.D. OFFICE OF PHARMACEUTICAL SCIENCE KEITH WEBBER, PH.D.

PROPOSED MILESTONES MILESTONESCHEDULE FINALIZE PROPOSALMARCH 2006 PRESENT TO ACPSAPRIL 2006 ESTABLISH PROCEDURESJULY 2006 SEND TO ACPSAUGUST 2006 ACPS TRAININGOCTOBER 2006 FIRST SITE-VISITDEC. 2006

ONE POSSIBLE MODEL FOR PERIODIC SITE VISITS ESTABLISH WORKING GROUP(S) WITH ACPS CHAIRED BY ACPS MEMBER(S) EXTERNAL AD HOC MEMBERS FOR EACH WG REVIEW PRINCIPAL INVESTIGATORS/TEAM LEADERS REPORT BACK TO ACPS FOR RATIFICATION OUTPUT: RECOMMENDATIONS TO OPS DIRECTOR

PROMOTIONS & CONVERSIONS -POSSIBLE MODEL- A SEPARATE PEER-REVIEW COMMITTEE COULD BE ESTABLISHED TO REVIEW PERSONNEL FOR PROMOTIONS & CONVERSIONS. THE COMMITTEE WOULD TAKE THE RECOMMENDATIONS FROM THE ACPS WORKING GROUP INTO ACCOUNT IN ITS DECISIONS.

DISCUSSION IN ADDITION TO SCIENTIFIC RIGOR, PRODUCTIVITY, MISSION RELEVANCE, AND WORKLOAD, ARE THERE OTHER FACTORS THAT SHOULD BE CONSIDERED IN ASSESSMENTS OF CDER RESEARCHERS (E.G., CREATIVITY, INNOVATION)? PLEASE RECOMMEND CRITERIA FOR ASSESSING PRODUCTIVITY FOR THE DIFFERENT TYPES OF RESEARCH PROJECTS (E.G., PUBLICATIONS, COMPLETED PROJECTS, ETC). WHAT RECOMMENDATIONS DO YOU HAVE WITH REGARD TO BUILDING A SINGLE SYSTEM TO ASSESS THE FULL SPECTRUM OF CDER RESEARCH PROGRAMS?